stockportfolio.pro
Haemonetics Corporation P/E Ratio 2009–2026
Haemonetics Corporation (HAE) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +0.7%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2026 | 27.49 | +43.2% |
| FY 2025 | 19.20 | -48.5% |
| FY 2024 | 37.27 | +0.9% |
| FY 2023 | 36.94 | -38.8% |
| FY 2022 | 60.32 | +39.0% |
| FY 2021 | 43.39 | -35.6% |
| FY 2020 | 67.34 | -19.9% |
| FY 2019 | 84.12 | -2.3% |
| FY 2018 | 86.07 | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | 140.37 | +188.6% |
| FY 2014 | 48.64 | -13.6% |
| FY 2013 | 56.30 | +110.1% |
| FY 2012 | 26.80 | +19.1% |
| FY 2011 | 22.50 | -12.9% |
| FY 2010 | 25.83 | +6.5% |
| FY 2009 | 24.26 | — |
Source: Haemonetics Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Haemonetics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHaemonetics Corporation — frequently asked questions
What is Haemonetics Corporation's price-to-earnings ratio?
Haemonetics Corporation (HAE) reported price-to-earnings ratio of 27.49 for fiscal year 2026, per its SEC filings.
How has Haemonetics Corporation's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2026, HAE's price-to-earnings ratio grew at roughly 0.7% per year (compound annual rate), from 24.26 to 27.49.
Where does this data come from?
Figures are computed from Haemonetics Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.